Skip to main content
    1. Home

    • UCB Medicines: Clinical Studies and Scientific Research Publication

    Publications

    This page contains links to basic science and clinical research published on UCB medicines and disease areas of focus. The information is limited to products that have been approved for use by the U.S. Food and Drug Administration (FDA) and may contain information that is not part of the FDA-approved Prescribing Information (eg, doses, uses, devices, populations). UCB, Inc. does not recommend or endorse the use of its products in a manner not consistent with the approved Prescribing Information. Please see the Full Prescribing Information for each product when making clinical decisions.

    Select product(s):
    Select topic(s):
    Phase:

    *Includes seizure clusters and acute or prolonged seizures

    164 result(s)

    phase 3

    BIMZELX® (bimekizumab-bkzx)

    Psoriatic Arthritis
    View

    Comparative Effectiveness of Bimekizumab and Secukinumab in Patients with Psoriatic Arthritis at 52 Weeks Using a Matching-Adjusted Indirect Comparison 

    Philip J Mease, Richard B Warren, Nash Peter et al.  March 06, 2024
    phase 3

    BIMZELX® (bimekizumab-bkzx)

    Plaque Psoriasis
    View

    Mental health outcomes in patients with moderate to severe psoriasis treated with bimekizumab: Analysis of phase 2/3 randomized trials

    Blauvelt Andrew, Armstrong April, Joseph F Merola et al.  March 04, 2024
    phase 4/RWE

    BRIVIACT® (brivaracetam) CV

    Focal Onset Seizures
    View

    Effectiveness and tolerability of brivaracetam in patients with epilepsy stratified by comorbidities and etiology in the real world: 12-month subgroup data from the international EXPERIENCE pooled analysis

    Jerzy P Szaflarski, Hervé Besson, Wendyl D'Souza et al.  March 04, 2024
    phase 2

    BIMZELX® (bimekizumab-bkzx)

    Plaque Psoriasis
    View

    Mental health outcomes in patients with moderate to severe psoriasis treated with bimekizumab: Analysis of phase 2/3 randomized trials

    Blauvelt Andrew, Armstrong April, Joseph F Merola et al.  March 04, 2024
    phase 3

    ZILBRYSQ® (zilucoplan)

    Generalized Myasthenia Gravis
    View

    Improvement of fatigue in generalised myasthenia gravis with zilucoplan

    Weiss D. Michael, Freimer Miriam, M. Isabel Leite et al.  February 24, 2024
    phase 3

    BIMZELX® (bimekizumab-bkzx)

    Psoriatic Arthritis
    View

    Bimekizumab treatment in patients with active psoriatic arthritis and prior inadequate response to tumour necrosis factor inhibitors: 52-week safety and efficacy from the phase III BE COMPLETE study and its open-label extension BE VITAL

    Coates C. Laura, Landewé B.M. Robert, Iain B McInnes et al.  February 22, 2024
    phase 3

    BIMZELX® (bimekizumab-bkzx)

    Psoriatic Arthritis
    View

    Improvement in work productivity among psoriatic arthritis patients treated with biologic or targeted synthetic drugs: a systematic literature review and meta-analysis in Arthritis Research and Therapy 

    Laure Gossec, Brittany Humphries, Megan Rutherford et al.  February 15, 2024
    phase 4/RWE

    BRIVIACT® (brivaracetam) CV

    Focal Onset Seizures
    View

    Conversion to brivaracetam monotherapy in clinical practice: a retrospective study

    Simona Lattanzi, Nicoletta Foschi, Chiara Martellino et al.  February 01, 2024
    phase 3

    BIMZELX® (bimekizumab-bkzx)

    Psoriatic Arthritis
    View

    Validity and score interpretation of the 12-item Psoriatic Arthritis Impact of Disease: an analysis of pooled data from two phase 3 trials of bimekizumab in patients with psoriatic arthritis 

    Gossec Laure, Orbai Ana-Maria, Laura C Coates et al.  January 31, 2024
    phase 3

    BIMZELX® (bimekizumab-bkzx)

    Psoriatic Arthritis
    View

    Bimekizumab for the treatment of psoriatic arthritis. 

    Tanaka Yoshiya, Shaw Stevan et al.  January 21, 2024